City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Brooklyn College

2021

Dose adjustment of antidiabetic medications in chronic kidney
disease
Matthew Salvatore Snyder
New York Institute of Technology

Joshua Fogel
CUNY Brooklyn College

Svetlana Pyatigorskaya
Nassau University Medical Center

Sofia Rubinstein
Nassau University Medical Center

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/bc_pubs/384
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

ORIGINAL ARTICLE

Dose adjustment of antidiabetic medications in
chronic kidney disease
Matthew Salvatore Snyder1, Joshua Fogel2, Svetlana Pyatigorskaya3, Sofia Rubinstein3
New York Institute of Technology College of Osteopathic Medicine, 101 Northern Boulevard, Old Westbury, NY, USA, 2Department of Business
Management, Brooklyn College, 218 Whitehead Hall, Brooklyn, NY, USA, 3Division of Nephrology and Hypertension, Nassau University Medical
Center, 2201 Hempstead Turnpike, East Meadow, NY, USA,
1

Access this article online

ABSTRACT
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Purpose: The purpose of this study is to identify whether Internal Medicine house-staff (IMHS)
have awareness and knowledge about the correct dosage of antidiabetic medications for
patients with chronic kidney disease (CKD), as dosing errors result in adverse patient outcomes
for those with diabetes mellitus (DM) and CKD. Methods: There were 353 IMHS surveyed to
evaluate incorrect level of awareness of medication dose adjustment in patients with CKD (ILA)
and incorrect level of knowledge of glomerular filtration rate level for medication adjustment
(ILK-GFR) for Glipizide, Pioglitazone, and Sitagliptin. Results: Lack of awareness and
knowledge was high, with the highest for Pioglitazone at 72.8%. For ILA, the percentages were:
Pioglitazone: 72.8%, Glipizide: 43.9%, and Sitagliptin: 42.8%. For ILK-GFR, the percentages
were: Pioglitazone: 72.8%, Glipizide: 68.3%, and Sitagliptin: 65.4%. Conclusions: IMHS have
poor awareness and knowledge for antidiabetic medication dose adjustment in patients with DM
and CKD. Both Electronic Medical Rerecord best practice advisory and physician–pharmacist
collaborative drug therapy management can enhance safe drug prescribing in patients with
CKD. In addition, IMHS’s practice for antidiabetic medication dose adjustment was better with
Nephrology exposure. A formal didactic educational training during medical school and residency
for antidiabetic medication dose adjustment in patients with DM and CKD is highly encouraged
to prevent medication dosing errors and to more effectively and safely allow IMHS to manage
complex treatment regimens.
Key words: Adult-onset diabetes mellitus, chronic kidney insufficiency, internal medicine,
medication error, residency and internship

INTRODUCTION
CKD is a global public health problem and in the United
States it affects more than 30 million people.[1,2] DM is a
leading risk factor for CKD in the United States.[1] Patients
with DM often use multiple medications to achieve glycemic
control and manage their comorbidities.[3] Patients with
CKD, DM, and particularly elderly patients with DM
are at high risk for adverse drug events (ADEs) from
polypharmacy due to the altered pharmacokinetics of parent
drugs and their metabolites.[4,5]
Address for correspondence: Dr. Sofia Rubinstein,
Division of Nephrology & Hypertension,
Nassau University Medical Center, Box 49,
2201 Hempstead Turnpike, East Meadow, NY 11554, USA.
E-mail: srubinst@numc.edu

A common cause of dose-related ADEs is failure to properly
adjust doses for renal dysfunction.[6] Almost half of the
patients with DM and CKD are treated only by primary care
physicians (PCPs), with a small number of patients being
comanaged by either endocrinologists or nephrologists.[7]
Half of all ADEs/ADE-related hospitalizations can be
prevented by avoiding inappropriate prescribing from
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PCPs.[8] Inappropriate dose prescribing also includes
medication dose modifications done by the hospital
medicine team, often Internal Medicine residency trainees
and graduates, on patient discharge and before patients
being seen by their PCPs.[9]
There does not appear to be any research about whether
IMHS possess the necessary awareness and knowledge
to prescribe the correct doses of antidiabetic medications
in patients with CKD. This study reports percentages for
incorrect level of awareness for antidiabetic medication dose
adjustment in patients with CKD (ILA) and also incorrect
level of knowledge of ILK-GFR for Glipizide, Pioglitazone,
and Sitagliptin in patients with impaired renal function.
This study conducts exploratory analyses to determine
potential variables associated with this incorrect awareness
and knowledge.

METHODS
There were 353 IMHS anonymously surveyed to assess
awareness and knowledge for dosage adjustment of commonly
used diabetes medications in patients with DM and CKD.
IMHS are those resident physician trainees that have obtained
either an MD, DO, or MBBS degree. Survey sites were six
hospitals located in the New York City metropolitan area. The
survey was distributed and collected at all hospitals before
the beginning of an IMHS conference. IMHS were included
across all levels of training. The study received IRB approval.
All participants provided informed consent.
Demographic variables were age (years), sex, training
level (PGY1, PGY2, PGY3 or greater), and medical
school graduate type (U.S. allopathic, U.S. osteopathic,
international medical school with U.S. clinical rotation,
international medical school without U.S. clinical rotation).
The kidney disease history variable consisted of the presence
of previous kidney problems among oneself, one’s children,
or significant other or any first-degree relatives. There were
a few variables about increased Nephrology exposure and
consisted of renal clinic experience of 10 or more times
attending a renal clinic as part of training, participating in
a Nephrology rotation in medical school, participating in a
Nephrology rotation in medical residency, and interest in
studying and training in Nephrology in the future.
We included the diabetes medications that were more
commonly prescribed by our hospital’s pharmacy. These
medications were Glipizide, Pioglitazone, and Sitagliptin.
Participants could choose to respond with the options listed
later for each diabetes medication. Diabetes medication (1)
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does not need dose adjustment, (2) needs dose adjustment at
glomerular filtration rate (GFR) <90 mL/min, (3) needs dose
adjustment at GFR<60 mL/min, (4) needs dose adjustment
at GFR <30 mL/min, and (5) I do not know.
We had two different outcomes for the IMHS. One of
the outcomes was to measure awareness for whether the
diabetes medication dose needed to be adjusted in the
setting of compromised renal function [“incorrect level of
awareness of medication dose adjustment in patients with
CKD (ILA)”]. The other outcome was to measure knowledge
for whether IMHS were knowledgeable about the level
of GFR that a specific medication for diabetes needed to
be adjusted [“incorrect level of knowledge of glomerular
filtration rate level for medication adjustment in patients
with CKD (ILK-GFR)”]. This knowledge was based on the
guidelines from the Physicians’ Desk Reference for dosing
these diabetes medications when treating patients with
CKD.[10] The Physicians’ Desk Reference compiles complete
United States Food and Drug Administration approved drug
label information.
Statistical analysis

Descriptive statistics were used with mean and standard
deviation for the continuous variables and frequency
and percentage for the categorical variables. Exploratory
multivariate logistic regression analyses were conducted
with the two different outcomes of ILA and ILK-GFR.
Predictors for these analyses included demographics (age,
sex), training characteristics (residency training level, type
of physician training), kidney disease personal/family
history, clinical training (renal clinic, Nephrology rotation
in medical school, Nephrology rotation in residency),
and further interest in Nephrology training. IBM SPSS
Statistics Version 22 was used for all analyses. All p-values
were two-sided.

RESULTS
The sample characteristics are described in Table 1. Mean
participant age was somewhat older than 29 years. The
sample had slightly less women. PGY2 and PGY3 and
greater each comprised approximately one-quarter. Almost
half consisted of international with U.S. clinical rotation
or international without U.S. clinical rotation. For kidney
disease history and participation substantially in renal
clinics, they were each reported by slightly more than onetenth. Both Nephrology rotation in medical school and
Nephrology rotation in residency were reported by slightly
more than one-quarter. Almost one-quarter had further
training interest in Nephrology.
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184
159
10

52.1
45.0
2.8

158
101
82
12

44.8
28.6
23.2
3.4

123
42
109

34.8
11.9
30.9

61

17.3

18
38
9
38
12
100

5.1
10.8
2.5
10.8
3.4
28.3

13
96
9
79

3.7
27.2
2.5
22.4

15

4.2

Note: SD = standard deviation. Sex above adds up to 99.99% due to rounding to
one decimal point. Precise percentages to total 100% are: men: 52.1246%, women:
45.0425%, and missing: 2.8329%.

80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0

72.8

43.9

68.3

72.8

65.4

42.8

ILA (Awareness)

Sitagliptine

Percent or
SD
2.95

Pioglitazone

Age (years) [mean]
Sex
Men
Women
Missing
Training
PGY1
PGY2
PGY3 and greater
Missing
School
U.S. allopathic
U.S. osteopathic
 International with U.S. clinical
rotation
 International without U.S. clinical
rotation
Missing
Kidney disease history (yes)
Missing
Renal clinic (yes)
Missing
Nephrology rotation medical school
(yes)
Missing
Nephrology rotation residency (yes)
Missing
Nephrology further training interest
(yes)
Missing

Frequency or
mean
29.2

Glipizide

Variables

Sitagliptine

Table 1: Descriptive statistics of a sample of 353 internal
medicine house-staff

Table 3 shows exploratory multivariate logistic regression
analyses for ILK-GFR. For Glipizide, PGY1 had statistically
significant higher odds as compared with the reference
group of PGY3 and greater for incorrect medication dose
needs adjustment at appropriate GFR level. Those with
international schooling without U.S. clinical rotation had
statistically significant higher odds as compared with the
reference group of U.S. allopathy for incorrect medication
dose needs adjustment at appropriate GFR level. Those
with a nephrology rotation during medical school had
statistically significant lower odds for incorrect medication
dose needs adjustment at appropriate GFR level. For
Pioglitazone, PGY2 had statistically significant higher
odds as compared with the reference group of PGY3 and
greater for incorrect medication dose needs adjustment
at appropriate GFR level. Also, those with international
schooling with U.S. clinical rotation had statistically
significant lower odds as compared with the reference
group of U.S. allopathy for incorrect medication dose
needs adjustment at appropriate GFR level. For Sitagliptin,
PGY1 had statistically significant higher odds as compared
with the reference group of PGY3 and greater for incorrect
medication dose needs adjustment at appropriate GFR
level. Those with a kidney disease history had statistically
significant lower odds for incorrect medication dose needs
adjustment at appropriate GFR level.

Pioglitazone

Table 2 shows exploratory multivariate logistic regression
analyses for ILA. For Glipizide, women had statistically
significant higher odds as compared with men for incorrect
medication dose needs adjustment. PGY1 had statistically
significant higher odds as compared with the reference
group of PGY3 and greater for incorrect medication
dose needs adjustment. For Pioglitazone, PGY2 had
statistically significant higher odds as compared with
the reference group of PGY3 and greater for incorrect
medication dose needs adjustment. Those with schooling
of international with U.S. clinical rotation had statistically
significant lower odds as compared with the reference
group of U.S. allopathy for incorrect medication dose
needs adjustment. For Sitagliptin, women had statistically
significant lower odds as compared with men for incorrect
medication dose needs adjustment. PGY1 had statistically

significant higher odds as compared with the reference
group of PGY3 and greater for incorrect medication dose
needs adjustment. Those with international schooling
with U.S. clinical rotation had statistically significant
higher odds as compared with the reference group of
U.S. allopathy for incorrect medication dose needs
adjustment. Those with a nephrology rotation during
residency had statistically significant lower odds for
incorrect medication dose needs adjustment.

Glipizide

Figure 1 shows percentages for perception of ILA and
ILK-GFR. For ILA, both Glipizide and Sitagliptin were
above 40% whereas Pioglitazone was above 70%. For ILKGFR, Pioglitazone had the same percentage whereas both
Glipizide and Sitagliptin increased to greater than 60%.

ILK-GFR (Knowledge)

Figure 1: Percentages for incorrect level of awareness of medication dose
needs adjustment (ILA) and incorrect level of knowledge of medication dose
needs adjustment at appropriate GFR level (ILK-GFR) for diabetes medications
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Table 2: Multivariate logistic regression analyses for incorrect level of awareness of medication dose needs adjustment
Variables
Age (years)
Sex (women)
Training
PGY3 and greater
PGY1
PGY2
School
U.S. allopathic
U.S. osteopathic
International with
U.S. clinical rotation
International without
U.S. clinical rotation
Kidney disease history
Renal clinic
Nephrology rotation medical
school
Nephrology rotation
residency
Nephrology further training
interest

GLI OR
1.00
1.73
Reference
group
4.55
2.05

95% CI
0.91, 1.11
1.03, 2.91

2.19, 9.45
0.94, 4.46

P-value
0.93
0.04

PIO OR
0.97
1.18

<0.001
0.07

Reference
group
1.98
2.33

95% CI
0.87, 1.07
0.65, 2.14

P-value
0.51
0.59

SIT OR
1.02
0.56

95% CI
0.93, 1.12
0.33, 0.95

P-value
0.73
0.03

0.06
0.04

Reference
group
3.06
1.54

1.52, 6.14
0.74, 3.24

0.002
0.25

0.16, 1.03
0.19, 0.80

0.06
0.01

Reference
group
1.68
2.59

0.74, 3.84
1.35, 4.97

0.22
0.004

0.97, 4.06
1.05, 5.14

Reference
group
1.64
0.91

0.70, 3.84
0.47, 1.75

0.25
0.78

Reference
group
0.40
0.39

1.60

0.72, 3.55

0.25

0.85

0.33, 2.17

0.73

1.46

0.66, 3.24

0.36

1.07
0.50
0.88

0.45, 2.52
0.19, 1.32
0.48, 1.60

0.88
0.16
0.68

1.44
1.28
1.21

0.51, 4.09
0.44, 3.67
0.62, 2.37

0.50
0.65
0.57

0.50
0.63
0.77

0.21, 1.21
0.25, 1.61
0.43, 1.37

0.12
0.33
0.37

0.69

0.38, 1.24

0.21

1.01

0.52, 1.96

0.97

0.56

0.31, 0.998

0.049

1.36

0.72, 2.56

0.35

1.56

0.73, 3.34

0.25

0.92

0.50, 1.71

0.79

Values that are bold/italics are those that are statistically significant
Note: GLI = Glipizide, PIO = Pioglitazone, SIT = Sitagliptin, OR = odds ratio, CI = confidence interval

Table 3: Multivariate logistic regression analyses for incorrect level of knowledge of medication dose needs adjustment
at appropriate GFR level
Variables
Age (years)
Sex (women)
Training
PGY3 and greater
PGY1
PGY2
School
U.S. allopathic
U.S. osteopathic
International with U.S. clinical
rotation
International without
U.S. clinical rotation
Kidney disease history
Renal clinic
Nephrology rotation medical
school
Nephrology rotation residency
Nephrology further training
interest

GLI OR
0.96
1.42
Reference
group
2.53
1.24

95% CI
0.87, 1.06
0.81, 2.51

1.23, 5.23
0.60, 2.55

p-value
0.40
0.22

PIO OR
0.97
1.18

0.01
0.57

Reference
group
1.98
2.33

95% CI
0.87, 1.07
0.65, 2.14

p-value
0.51
0.59

SIT OR
1.00
0.79

95% CI
0.91, 1.10
0.46, 1.34

p-value
0.96
0.37

0.06
0.04

Reference
group
2.32
1.36

1.17. 4.61
0.68, 2.72

0.02
0.39

0.16, 1.03
0.19, 0.80

0.06
0.01

Reference
group
1.28
1.70

0.55, 2.98
0.88, 3.31

0.57
0.12

0.97, 4.06
1.05, 5.14

Reference
group
1.27
1.91

0.51, 3.11
0.94, 3.87

0.61
0.07

Reference
group
0.40
0.39

3.13

1.26, 7.77

0.01

0.85

0.33, 2.17

0.73

1.97

0.86, 4.50

0.11

1.94
0.77
0.52

0.72, 5.22
0.30, 1.99
0.28, 0.97

0.19
0.59
0.04

1.44
1.28
1.21

0.51, 4.09
0.44, 3.67
0.62, 2.37

0.50
0.65
0.57

0.43
0.74
0.61

0.19, 0.97
0.30, 1.83
0.34, 1.09

0.04
0.52
0.10

0.73
1.75

0.40, 1.35
0.84, 3.65

0.32
0.14

1.01
1.56

0.52, 1.96
0.73, 3.34

0.97
0.25

0.81
1.01

0.45, 1.43
0.53, 1.92

0.46
0.99

Values that are bold/italics are those that are statistically significant
Note: GLI = Glipizide, PIO = Pioglitazone, SIT = Sitagliptin, OR = odds ratio, CI = confidence interval

DISCUSSION
This study found that there were high percentages and
high odds for incorrect level of awareness of medication
dose adjustment in patients with CKD (ILA) and incorrect
level of knowledge of ILK-GFR in patients with CKD for
Glipizide, Pioglitazone, and Sitagliptin among IMHS [see
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Figure 1]. Exploratory analyses for antidiabetic medications
showed that PGY1 and PGY2 had higher odds for both ILA
and ILK-GFR. Graduates of international medical schools
without U.S. clinical rotations had higher odds for ILK-GFR
for Glipizide. IMHS with greater exposure to nephrology
(i.e. Nephrology rotation in medical school or residency and
personal/family history of kidney disease) had lower odds
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of ILA or ILK-GFR. Women and graduates of international
medical schools with U.S. clinical rotations had mixed
patterns for ILA or ILK-GFR. Women had higher odds for
ILA with Glipizide but lower odds for ILA with Sitagliptin.
Graduates of international medical schools with U.S. clinical
rotations had higher odds for ILA with Sitagliptin but lower
odds for ILA and ILK-GFR with Pioglitazone.
ILA and ILK-GFR were highest in Pioglitazone, with almost
three-quarters of IMHS responding incorrectly to dose
adjustments. For Glipizide and Sitagliptin, almost half of
IMHS responded incorrectly to dose adjustments for ILA
and about two-thirds for ILK-GFR. The current study results
are similar to international findings, which showed that
prescribers did not make adequate drug dose adjustments
for two-thirds of antidiabetic medications and in 29–74%
of patients with renal impairment.[11,12] Recently, some
European and many South Asian countries suspended
Pioglitazone use due its adverse side-effect profile.[13] This
could have led to decreased focus on education about
Pioglitazone and, consequently, decreased awareness and
knowledge among the IMHS that trained or worked in
these countries. Glipizide is a well-established antidiabetic
medication with recognized deleterious side-effects of
hypoglycemia and weight gain.[14] As Sitagliptin is a relatively
new medication with a better and safer side-effect profile,[14,15]
more robust efforts were provided to educate clinicians
about its use.[16] These medication attributes likely resulted
in greater didactic focus and may have been the reason
for the somewhat improved awareness and knowledge,
although overall both were still quite poor. One potential
explanation for the overall poor awareness and knowledge
for dose adjusting among IMHS is didactic emphasis on use
of antidiabetic medications in the general DM population
rather than in those with CKD.[17]
To improve patient safety, it is important to implement strategies
to prevent medication dosing errors. Having additional
nephrology education either in medical school or in residency
is associated with improved level of awareness and knowledge
among IMHS.[18] Both internal medicine residents and PCPs
have gaps in their knowledge of CKD practice guidelines and
treatment of CKD complications.[19] Improved education of
CKD among training physicians can result in improved patient
care and clinical outcomes.[18] This may come in the form of
additional ambulatory Nephrology exposure as conditions such
as CKD are best taught in the outpatient setting.[20]
Another strategy to improve patient safety and quality of
patient care is to implement an Electronic Medical Record
(EMR) best practice advisory. As EMR is now being widely

adopted across the United States, it provides a unique
opportunity to minimize dosing errors by supporting
enhanced adherence to clinical dosing guidelines in both
inpatient and outpatient settings.[21] The EMR can support
a complex, dynamic, medical decision-making process
that results in improved medication management by
enabling more accurate, comprehensive, and automated
medication prescribing and delivery.[22] In addition to
improving medication documentation, identification
of patients affected by a drug recall, and managing
prescriptions for controlled drugs more effectively, the
EMR advisory can identify and flag drug interactions,
and ensure appropriate and safe drug prescribing for the
level of CKD.[23]
Pharmacist support provides another level of enhanced
patient safety and medication dosing optimization in
patients with CKD.[24] Pharmacists integrated in ambulatory
care reduce hospitalizations by more than 20%, resulting
in significant cost savings per patient. [25] Despite the
overwhelmingly positive impact of pharmacist services
on patient outcomes, the integration of pharmacists
in ambulatory care programs is not widespread. This
is a missed opportunity as collaborative care between
pharmacists and physicians improves pharmacotherapeutic
outcomes and provides increased value and efficiency to
the health-care system.[24] The three types of pharmacist
collaborative care models: (1) a pharmacist with physician
oversight, (2) pharmacist–interprofessional teams, and
(3) physician–pharmacist teams that are being suggested
for physician–pharmacist collaborative drug therapy
management have demonstrated the positive impact
in patients with chronic conditions, including DM and
CKD.[24]
The data from our study are very similar to data reported
from IMHS training in the United States and, therefore,
can be generalizable. In a report for those training in the
2015–2016 academic year, the ACGME reported that 24,983
IMHS participated in training in the United States.[26] Our
study reported a mean age of 29.2 years and with a sex
representation at 45% from females. Our study is similar
to the data reported from the U.S. national training data
of IMHS with a mean age of 29.3 years and with a sex
representation at 41% from females.[26] Our sample from
New York State reported 48.2% IMGS, which is similar to the
ACGME report of 41.2% IMGs for the whole New York State
and 40.0% throughout the United States.[26] The training level
from our sample for each level of training is similar to the
statistics overall in the United States: 44.8% current sample
versus 39.9% U.S. national for PGY1 trainees, 28.6% current
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sample versus 30.7% U.S. national for PGY2 trainees, and
23.2% current sample versus 29.4% U.S. national for PGY3
trainees.[26]
A strength of our study is that we did not allow the physicians
participating to use computer-based or cellular-phone-based
apps or programs to assist in answering our survey questions
about prescription dose adjustment and thus we are best
measuring physician awareness and knowledge. We agree
that these apps and programs are potentially available in
clinical practice. However, physicians are busy and typically
do not often use these apps and programs.[27] The study has
several limitations. First, our study is from one geographic
area and may not generalize to other areas. Second, we
chose medications based on what diabetes medications are
often prescribed at our institution. Each institution may
have different preferences for the medications used to treat
diabetes. Third, we did not include Endocrinology rotation as
a variable. It is possible that an Endocrinology rotation could
be comparable to Nephrology rotation with the exposure to
a daily prescription of antidiabetic medications. Fourth, it
is also possible that results might slightly differ if someone
had more than one exposure from the three Nephrology
clinical training variables. Fifth, there is the possibility of
recall bias in the self-reported survey responses.
In conclusion, there was an overall poor awareness and
knowledge among IMHS for proper dose adjustments
with antidiabetic medications in patients with CKD. Poor
knowledge of renal dosing guidelines has been identified as a
major cause of prescribing errors and the resulting morbidity
and occasionally mortality.[6,8] It appears that current
medical education and training has deficiencies in the
area of medication dose adjustment for renal dysfunction,
thus potentially negatively impacting patient safety. Both
EMR best practice advisory and physician–pharmacist
collaborative drug therapy management can improve patient
safety by appropriate adjustment of medications in patients
with CKD. The role of PCPs in the management of patients
with DM and CKD is becoming more essential due to
the increasing prevalence of both DM and CKD.[2,6] As
PCPs prescribe the majority of antidiabetic medications,
it is essential that IMHS receive more Nephrology clinical
exposure and formal didactic educational training during
residency for dose adjustment in patients with CKD. This
can ensure appropriate and safe prescribing.
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